pdfNCA: NCA output to pdf file

In ncar: Noncompartmental Analysis for Pharmacokinetic Report

NCA output to pdf file

Description

This output NCA result in a pdf file.

Usage

pdfNCA(fileName = "Temp-NCA.pdf", concData, key = "Subject", colTime = "Time", 
       colConc = "conc", dose = 0, adm = "Extravascular", dur = 0, 
       doseUnit = "mg", timeUnit = "h", concUnit = "ug/L", down="Linear", 
       R2ADJ = 0, MW = 0, SS = FALSE, iAUC = "", excludeDelta = 1, UsePoints = NULL,
       performedBy = "")

Arguments

fileName	file name to save
concData	concentration data table
key	column names of concData to be shown in the output table
colTime	column name for time
colConc	column name for concentration
dose	administered dose, a scalar or a vector
adm	one of "Bolus" or "Infusion" or "Extravascular" to indicate drug administration mode
dur	duration of infusion, a scalar or a vector
doseUnit	unit of dose
timeUnit	unit of time
concUnit	unit of concentration
down	either of "Linear" or "Log" to indicate the way to calculate AUC and AUMC
R2ADJ	Minimum adjusted R-square value to determine terminal slope automatically
MW	molecular weight of drug
SS	if steady-state, this should be TRUE. AUCLST (AUClast) is used instead of AUCIFO (AUCinf) for the calculation of Vz (VZFO, VZO), CL (CLFO, CLO), and Vdss (VSSO).
iAUC	interval AUC information in a dataframe with "Name", "Start", and "End" columns
excludeDelta	Improvement of R2ADJ larger than this value could exclude the last point. Default value 1 is for the compatibility with other software. Author recommends to use excludeDelta option with about 0.3.
UsePoints	A list of length equal to the number of subjects/NCAs. Each element is a vector of indices of points to calculate terminal slope for the corresponding subject. Values of use points should not be zero. Use only when automatic determination is not satisfactory. If this is used, R2ADJ option is ignored.
performedBy	name of the person performing the analysis, printed on the first (title) page above the Performed by / Reviewed by approval lines.

Value

CMAX	maximum concentration, Cmax
CMAXD	dose normalized Cmax, CMAX / Dose, Cmax / Dose
TMAX	time of maximum concentration, Tmax
TLAG	time to observe the first non-zero concentration, for extravascular administration only
CLST	last positive concentration observed, Clast
CLSTP	last positive concentration predicted, Clast_pred
TLST	time of last positive concentration, Tlast
LAMZHL	half-life by lambda z, ln(2)/LAMZ
LAMZ	lambda_z negative of best fit terminal slope
LAMZLL	earliest time for LAMZ
LAMZUL	last time for LAMZ
LAMZNPT	number of points for LAMZ
CORRXY	correlation of log(concentration) and time
R2	R-squared
R2ADJ	R-squared adjusted
C0	back extrapolated concentration at time 0, for bolus intravascular administration only
AUCLST	AUC from 0 to TLST
AUCALL	AUC using all the given points, including trailing zero concentrations
AUCIFO	AUC infinity observed
AUCIFOD	AUCIFO / Dose
AUCIFP	AUC infinity predicted using CLSTP instead of CLST
AUCIFPD	AUCIFP / Dose
AUCPEO	AUC % extrapolation observed
AUCPEP	AUC % extrapolated for AUCIFP
AUCPBEO	AUC % back extrapolation observed, for bolus IV administration only
AUCPBEP	AUC % back extrapolation predicted with AUCIFP, for bolus IV administration only
AUMCLST	AUMC to the TLST
AUMCIFO	AUMC infinity observed using CLST
AUMCIFP	AUMC infinity determined by CLSTP
AUMCPEO	AUMC % extrapolated observed
AUMCPEP	AUMC % extrapolated predicted
MRTIVLST	mean residence time (MRT) to TLST, for intravascular administration
MRTIVIFO	mean residence time (MRT) infinity using CLST, for intravascular administration
MRTIVIFP	mean residence time (MRT) infinity using CLSTP, for intravascular administration
MRTEVLST	mean residence time (MRT) to TLST, for extravascular administration
MRTEVIFO	mean residence time (MRT) infinity using CLST, for extravascular administration
MRTEVIFP	mean residence time (MRT) infinity using CLSTP, for extravascular administration
VZO	volume of distribution determined by LAMZ and AUCIFO, for intravascular administration
VZP	volume of distribution determined by LAMZ and AUCIFP, for intravascular administration
VZFO	VZO for extravascular administration, VZO/F, F is bioavailability
VZFP	VZP for extravascular administration, VZP/F, F is bioavailability
CLO	clearance using AUCIFO, for intravascular administration
CLP	clearance using AUCIFP, for intravascular administration
CLFO	CLO for extravascular administration, CLO/F, F is bioavailability
CLFP	CLP for extravascular administration, CLP/F, F is bioavailability
VSSO	volume of distribution at steady state using CLST, for intravascular administration only
VSSP	volume of distribution at stead state using CLSTP, for intravascular administration only

Author(s)

Kyun-Seop Bae <[e-mail]>

See Also

help, txtNCA, rtfNCA

Examples

#pdfNCA(fileName="NCA-Theoph.pdf", Theoph, key="Subject", colTime="Time", 
#       colConc="conc", dose=320, doseUnit="mg", timeUnit="h", concUnit="mg/L")
#pdfNCA(fileName="NCA-Theoph.pdf", Theoph, key=c("Subject", "Wt"), colTime="Time",
#       colConc="conc", dose=320, doseUnit="mg", timeUnit="h", concUnit="mg/L")
#pdfNCA(fileName="NCA-Indometh.pdf", Indometh, key="Subject", colTime="time", 
#       colConc="conc", adm="Infusion", dur=0.5, dose=25, doseUnit="mg", 
#       timeUnit="h", concUnit="mg/L")

ncar documentation built on July 20, 2026, 5:07 p.m.